GlaxoSmithKline is giving up on manufacturing in Costa Rica and will wind down operations at its plant in San Jose over the next three years.

GlaxoSmithKline is moving forward with a new plant in Scotland to expand API production for its COPD drug Ventolin, which has been one of the bright spots in…

The market for hepatitis C drugs is shrinking. Shortly after spending $3.9 billion on Idenix, Merck is taking a $2.9 billion hit on an experimental compound.

Swedish CDMO Recipharm has been on a buying and expansion binge for several years and saw it pay off with a significant jump in revenues last year.

Zhejiang Bangli Medical Products, a medical dressing manufacturer in China, received a warning letter for limiting an FDA inspection.

Dr. Reddy’s had hoped to start moving beyond an FDA warning letter that lambasted three of its India plants for data integrity and other issues in 2015, but…

Sun Pharma’s Ranbaxy unit has started work on a manufacturing plant in Egypt, a project that got under way well before Sun bought Ranbaxy in 2015.

India’s Granules will do a significant expansion of its API bulk drug site in Vishakhapatnam, and is getting substantial help from the International Finance…

Manufacturing